NF-kappa B pp 579-591 | Cite as

Sneaking-Ligand Fusion Proteins Attenuate Serum Transfer Arthritis by Endothelium-Targeted NF-κB Inhibition

  • Bettina Sehnert
  • Harald Burkhardt
  • Michael J. May
  • Jochen Zwerina
  • Reinhard E. Voll
Part of the Methods in Molecular Biology book series (MIMB, volume 1280)


The nuclear transcription factor κB (NF-κB) is a crucial mediator of the inflammatory and immune response. The contribution of dysregulated NF-κB is established in the pathogenesis of arthritis. Accordingly, NF-κB represents an attractive molecular target for the development of therapeutic interventions in inflammatory diseases. However, ubiquitous pharmacologic suppression of NF-κB activity is limited by the hazards of toxic side effects and profound immunosuppression. Cell type-specific NF-κB inhibition with the “sneaking-ligand” approach could identify disease-relevant cell types and improve risk-benefit ratios of therapeutic interventions. Vascular endothelial cells act as a gatekeeper and are crucial for leukocyte recruitment into sites of inflammation. The endothelium-specific NF-κB inhibitor SLC1 ameliorates serum transfer arthritis in mice and protects against inflammation and cartilage destruction. In this chapter, we describe the SLC1 treatment schedule in the K/BxN serum transfer arthritis and present the evaluation system to analyze arthritis severity and histopathological alterations.

Key words

NF-κB Endothelium Sneaking-ligand approach Mouse model Arthritis 



The work in the author’s laboratory was supported by the German Research Foundation (SFB 643 project B3 and A8; FOR 832, project 7; Sachbeihilfe DU337/3-2 and BU 584/4-1), BMBF 01EO0803 Grant to the Centre of Chronic Immunodeficiency, the Federal State of Hessen (LOEWE-Project: Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University Frankfurt), the German Federal Ministry of Education and Research ArthroMark (project 4, 01 EC 1009C), and National Institutes of Health/National Heart, Lung, and Blood Institute Grant RO1HL096642.


  1. 1.
    Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361CrossRefPubMedGoogle Scholar
  2. 2.
    McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219CrossRefPubMedGoogle Scholar
  3. 3.
    Williams MR, Azcutia V, Newton G et al (2011) Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol 32:461–469CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3:200–206CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Simmonds RE, Foxwell BM (2008) Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 47:584–590CrossRefGoogle Scholar
  6. 6.
    Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132:344–362CrossRefPubMedGoogle Scholar
  7. 7.
    May MJ, Marienfeld RB, Ghosh S (2002) Characterization of the Ikappa B-kinase NEMO binding domain. J Biol Chem 277:45992–46000CrossRefPubMedGoogle Scholar
  8. 8.
    Sehnert B, Burkhardt H, Wessels JT et al (2013) NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A 110:16556–16561CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Terato K, Hasty KA, Reife RA et al (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148:2103–2108PubMedGoogle Scholar
  10. 10.
    Nandakumar KS, Holmdahl R (2006) Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 8:223CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179–204CrossRefPubMedGoogle Scholar
  12. 12.
    Maccioni M, Zeder-Lutz G, Huang H et al (2002) Arthritogenic monoclonal antibodies from K/BxN mice. J Exp Med 195:1071–1077CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Bettina Sehnert
    • 1
  • Harald Burkhardt
    • 2
  • Michael J. May
    • 3
  • Jochen Zwerina
    • 4
  • Reinhard E. Voll
    • 1
  1. 1.Department of Rheumatology and Clinical Immunology and Centre of Chronic ImmunodeficiencyUniversity Medical Centre and University of FreiburgFreiburgGermany
  2. 2.Division of Rheumatology, Department of Internal Medicine II and Fraunhofer IME-Project-Group Translational Medicine and PharmacologyJohann Wolfgang Goethe University Frankfurt am MainFrankfurt am MainGermany
  3. 3.School of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  4. 4.Department of Internal Medicine 3University of Erlangen-NürnbergErlangenGermany

Personalised recommendations